Compare TBPH & STAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | STAA |
|---|---|---|
| Founded | 2013 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.9M | 867.9M |
| IPO Year | 2013 | 1995 |
| Metric | TBPH | STAA |
|---|---|---|
| Price | $16.45 | $21.15 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 9 |
| Target Price | $18.40 | ★ $22.19 |
| AVG Volume (30 Days) | 528.6K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 279.13 | N/A |
| EPS | ★ 2.06 | N/A |
| Revenue | $15,386,000.00 | ★ $239,442,000.00 |
| Revenue This Year | $1.04 | $27.04 |
| Revenue Next Year | N/A | $7.27 |
| P/E Ratio | $8.05 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.12 | $15.12 |
| 52 Week High | $21.03 | $30.81 |
| Indicator | TBPH | STAA |
|---|---|---|
| Relative Strength Index (RSI) | 58.98 | 65.19 |
| Support Level | $13.41 | $16.60 |
| Resistance Level | $19.04 | $27.80 |
| Average True Range (ATR) | 0.53 | 1.02 |
| MACD | 0.37 | 0.34 |
| Stochastic Oscillator | 99.04 | 90.72 |
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.